SyneuRx International (Taiwan) Past Earnings Performance
Past criteria checks 0/6
SyneuRx International (Taiwan)'s earnings have been declining at an average annual rate of -2.9%, while the Pharmaceuticals industry saw earnings growing at 18.5% annually.
Key information
-2.9%
Earnings growth rate
0.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | n/a |
| Return on equity | -118.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How SyneuRx International (Taiwan) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -329 | 48 | 286 |
| 31 Mar 22 | 0 | -322 | 47 | 278 |
| 31 Dec 21 | 0 | -315 | 46 | 270 |
| 30 Sep 21 | 0 | -294 | 42 | 249 |
| 30 Jun 21 | 0 | -273 | 39 | 228 |
| 31 Mar 21 | 0 | -246 | 38 | 201 |
| 31 Dec 20 | 0 | -219 | 37 | 175 |
| 30 Sep 20 | 0 | -224 | 39 | 180 |
| 30 Jun 20 | 0 | -229 | 41 | 184 |
| 31 Mar 20 | 0 | -226 | 41 | 183 |
| 31 Dec 19 | 0 | -223 | 41 | 182 |
| 30 Sep 19 | 0 | -215 | 40 | 179 |
| 30 Jun 19 | 0 | -206 | 39 | 175 |
| 31 Mar 19 | 0 | -205 | 39 | 177 |
| 31 Dec 18 | 0 | -204 | 38 | 179 |
| 30 Sep 18 | 0 | -241 | 39 | 211 |
| 30 Jun 18 | 0 | -277 | 40 | 243 |
| 31 Mar 18 | 0 | -304 | 41 | 252 |
| 31 Dec 17 | 0 | -332 | 43 | 262 |
| 30 Sep 17 | 0 | -278 | 42 | 212 |
| 30 Jun 17 | 0 | -224 | 41 | 162 |
| 31 Mar 17 | 0 | -193 | 39 | 143 |
| 31 Dec 16 | 0 | -163 | 38 | 125 |
| 30 Sep 16 | 0 | -140 | 35 | 114 |
| 30 Jun 16 | 0 | -116 | 33 | 104 |
Quality Earnings: 6575 is currently unprofitable.
Growing Profit Margin: 6575 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6575 is unprofitable, and losses have increased over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare 6575's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6575 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.2%).
Return on Equity
High ROE: 6575 has a negative Return on Equity (-118.93%), as it is currently unprofitable.